What is KeyCorp’s Estimate for RPID FY2024 Earnings?

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) – Equities research analysts at KeyCorp issued their FY2024 EPS estimates for shares of Rapid Micro Biosystems in a research note issued to investors on Tuesday, February 11th. KeyCorp analyst P. Knight forecasts that the company will earn ($1.10) per share for the year. KeyCorp currently has a “Strong-Buy” rating on the stock. The consensus estimate for Rapid Micro Biosystems’ current full-year earnings is ($1.09) per share. KeyCorp also issued estimates for Rapid Micro Biosystems’ Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.97) EPS and FY2026 earnings at ($0.82) EPS.

Rapid Micro Biosystems Price Performance

NASDAQ RPID opened at $3.48 on Friday. The firm has a market capitalization of $149.74 million, a PE ratio of -3.11 and a beta of 1.26. Rapid Micro Biosystems has a 12 month low of $0.58 and a 12 month high of $3.75. The company’s 50 day simple moving average is $1.50 and its 200 day simple moving average is $1.13.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Rapid Micro Biosystems stock. Renaissance Technologies LLC boosted its holdings in Rapid Micro Biosystems, Inc. (NASDAQ:RPID) by 122.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 183,087 shares of the company’s stock after buying an additional 100,942 shares during the quarter. Renaissance Technologies LLC owned 0.43% of Rapid Micro Biosystems worth $165,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 52.60% of the company’s stock.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.